Prosecution Insights
Last updated: April 19, 2026
Application No. 17/119,776

CHANNEL MODULATORS

Non-Final OA §DP
Filed
Dec 11, 2020
Examiner
CHERNYSHEV, OLGA N
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ocunexus Therapeutics Inc.
OA Round
5 (Non-Final)
54%
Grant Probability
Moderate
5-6
OA Rounds
3y 2m
To Grant
89%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
512 granted / 942 resolved
-5.6% vs TC avg
Strong +34% interview lift
Without
With
+34.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
44 currently pending
Career history
986
Total Applications
across all art units

Statute-Specific Performance

§101
14.8%
-25.2% vs TC avg
§103
8.6%
-31.4% vs TC avg
§102
12.6%
-27.4% vs TC avg
§112
45.6%
+5.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 942 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Continued Examination Under 37 CFR 1.114 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 13, 2026 has been entered. Response to Amendment 2. Claims 74, 97, 100, 105 and 107-109 have been amended and claims 111-117 added as requested in the amendment filed on March 13, 2026. Following the amendment, claims 74-77 and 79-117 are pending in the instant application. 3. The amendment to the claims filed on March 13, 2026 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121, as amended on June 30, 2003 (see 68 Fed. Reg. 38611, Jun. 30, 2003) with respect to claim 105. Specifically, claim 105 is presented as “previously presented” claim; however, the claim contains markings, which is permissible only for claims of the status “currently amended.” Appropriate correction is required. 4. Claims 74-77 and 79-117 are under examination in the instant office action. 5. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant’s response and withdrawn. 6. The Declaration of Prof. Colin R. Green under 37 CFR 1.132 filed March 13, 2026 is sufficient to overcome the rejection of the pending claims based upon 35 U.S.C. 102 and 103, see previous office actions of record. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 7. Claims 74-77, 79-96 and 99-117 are rejected on the ground of nonstatutory double patenting as being unpatentable over at least claims 1, 5 and 9 of U.S. Patent No. 7,098,190 for reasons of record in section 8 of Paper mailed on September 03, 2024 and section 9 of Paper mailed on April 14, 2025. 8. Claims 74-77, 79-96 and 99-117 are further rejected on the ground of nonstatutory double patenting as being unpatentable over at least claims 1-4 of U.S. Patent No. 7,615,540, reference 1 of IDS filed on 07/29/2024 for reasons of record in section 9 of Paper mailed on September 03, 2024 and section 10 of Paper mailed on April 14, 2025. 9. Claims 74-77, 79-96 and 99-117 are rejected on the ground of nonstatutory double patenting as being unpatentable over at least claims 1, 6 and 9 of U.S. Patent No. 7,879,811 for reasons of record in section 10 of Paper mailed on September 03, 2024 and section 11 of Paper mailed on April 14, 2025. 10. Claims 97, 98 and 111 are rejected on the ground of nonstatutory double patenting as being unpatentable over at least claims 1-3 of U.S. Patent No. 9,193,754 for reasons of record in section 11 of Paper mailed on September 03, 2024 and section 12 of Paper mailed on April 14, 2025. 11. Claims 97, 98 and 111 are further rejected on the ground of nonstatutory double patenting as being unpatentable over at least claims 1-2 of U.S. Patent No. 7,919,474 for reasons of record in section 12 of Paper mailed on September 03, 2024 and section 13 of Paper mailed on April 14, 2025. Conclusion 12. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA N CHERNYSHEV whose telephone number is (571)272-0870. The examiner can normally be reached 9AM to 5:30PM, Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA N CHERNYSHEV/Primary Examiner, Art Unit 1675 March 25, 2026
Read full office action

Prosecution Timeline

Dec 11, 2020
Application Filed
Sep 15, 2021
Response after Non-Final Action
Mar 31, 2023
Response after Non-Final Action
Dec 06, 2023
Non-Final Rejection — §DP
Mar 12, 2024
Response Filed
Apr 24, 2024
Final Rejection — §DP
Jun 25, 2024
Applicant Interview (Telephonic)
Jun 25, 2024
Examiner Interview Summary
Jul 29, 2024
Request for Continued Examination
Aug 02, 2024
Response after Non-Final Action
Aug 28, 2024
Non-Final Rejection — §DP
Mar 03, 2025
Response Filed
Apr 09, 2025
Final Rejection — §DP
Oct 13, 2025
Notice of Allowance
Mar 13, 2026
Request for Continued Examination
Mar 13, 2026
Response after Non-Final Action
Mar 18, 2026
Response after Non-Final Action
Mar 25, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601750
DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET
2y 5m to grant Granted Apr 14, 2026
Patent 12601751
PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12596126
METHODS FOR THE PREDICTION, PROGNOSIS, AND/OR DIAGNOSIS OF AN INFLAMMATORY RESPONSE ASSOCIATED WITH SCHIZOPHRENIA
2y 5m to grant Granted Apr 07, 2026
Patent 12589098
METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
2y 5m to grant Granted Mar 31, 2026
Patent 12582693
GLUTATHIONE TRISULFIDE (GSSSG) IN NEUROPROTECTION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
54%
Grant Probability
89%
With Interview (+34.4%)
3y 2m
Median Time to Grant
High
PTA Risk
Based on 942 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month